AZD0486, AZD0486, TOCILIZUMAB
D7405C00001 (SYRUS)
Phase 2 small_molecule active
Quick answer
AZD0486, AZD0486, TOCILIZUMAB for B-Cell Acute Lymphoblastic Leukaemia is a Phase 2 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- B-Cell Acute Lymphoblastic Leukaemia
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active